停用抗精神病药后的不良事件:个体参与者数据荟萃分析
该个体参与者数据荟萃分析纳入18项安慰剂对照抗精神病药随机对照试验,比较停药组(692例)与对照组(935例)。停药组新发躯体不良事件43% vs 对照组31%(OR 1.74,95%CI 1.27-2.39),新发精神不良事件也更频繁(OR 2.01,95%CI 1.38-2.94)。作者认为逐渐减停可降低新发躯体不良事件风险。
要点
- 停药组新发躯体不良事件风险高于对照组(OR 1.74,95%CI 1.27-2.39),证据强度中等。
- 停药组新发精神不良事件也更频繁(OR 2.01,95%CI 1.38-2.94)。
- 逐渐减停相比突然停药与新发躯体不良事件概率降低相关(OR 0.54,95%CI 0.32-0.91)。
核心结论
- 作者发现中等强度证据表明停用第一代和第二代抗精神病药后可出现新发躯体不良事件,尤其在较长疗程停药后。
- 作者认为逐渐减停可减轻停用抗精神病药后新发躯体不良事件的风险。
研究设计与样本
- 两阶段个体参与者数据荟萃分析,检索Yale University Open Data Access Project数据库从建库至2021年5月6日的抗精神病药随机对照试验。
- 纳入安慰剂对照抗精神病药随机对照试验,参与者为年龄≥18岁、任何性别和种族的精神分裂症、分裂情感性障碍或双相障碍患者。
- 从筛选或清洗期开始,将随机分至安慰剂组的参与者分为停药组(692例)和对照组(935例)。
- 排除在基线前4周内停用抗抑郁药、锂盐或抗癫痫药者,或接受抗精神病药耐受性试验者,或基线前12周内接受长效抗精神病药注射者。
主要发现
- 停药组新发躯体不良事件295例(43%),对照组293例(31%),OR 1.74(95%CI 1.27-2.39;τ²=0.15;证据强度中等)。
- 停药组新发精神不良事件较对照组更频繁(OR 2.01;95%CI 1.38-2.94)。
- 停药前治疗疗程较长(治疗疗程加倍OR 1.08;95%CI 1.01-1.14)与停药后新发躯体不良事件概率较高相关。
- 逐渐减停相比突然停药(OR 0.54;95%CI 0.32-0.91)及无躯体疾病史相比有躯体疾病史(OR 0.63;95%CI 0.43-0.91)与新发躯体不良事件概率较低相关。
- 偏倚风险:13项(72.2%)研究为中等,5项(27.8%)研究为严重。
临床怎么用
- 作者认为这些发现对停药安全性有启示,可用于制定个体化治疗计划。
- 作者认为逐渐减停可减轻停用抗精神病药后新发躯体不良事件的风险。
局限性
- 13项(72.2%)研究的偏倚风险为中等,5项(27.8%)研究的偏倚风险为严重。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adverse events can occur after antipsychotic discontinuation but evidence from antipsychotic drug trials is scarce. We aimed to estimate the occurrence of adverse events after discontinuing antipsychotics. METHODS: For this two-stage individual participant data meta-analysis, we searched the Yale University Open Data Access Project's database for randomised controlled trials of antipsychotics from database inception until May 6, 2021. We included placebo-controlled antipsychotic randomised controlled trials with individual participant data of participants (aged ≥ 18 years, of any sex and ethnicity) with schizophrenia, schizoaffective disorder, or bipolar disorder. Studies were excluded if treatment with antidepressants, lithium, or antiepileptic drugs was initiated as additive therapy at the start of the placebo phase. Starting from the screening or washout phase, we divided participants who were randomised to placebo into two groups: the discontinuation group (participants who discontinued prestudy antipsychotics at the start of the screening or washout phase) and control group (participants who did not take prestudy antipsychotics for at least 4 weeks before the start of the screening or washout phase). Participants were excluded from the discontinuation and control groups if they discontinued prestudy treatment with antidepressants, lithium, or antiepileptic drugs up to 4 weeks before baseline, received an antipsychotic as a tolerability test, or received a long-acting injection of an antipsychotic within 12 weeks before baseline. In the discontinuation group, individuals were excluded if they discontinued prestudy antipsychotic treatment more than 3 days before, or any day after, the start of screening or washout phase. The prespecified primary outcome was occurrence of at least one new somatic adverse event with an onset within 4 weeks after the start of the screening or washout phase. We implemented a generalised linear model that accounted for potential confounders, to estimate the effect of antipsychotic discontinuation. This study is registered with PROSPERO (CRD42021224350). FINDINGS: We identified 409 records of which 18 were eligible and included in the analysis. From these 18 studies, 692 individuals (242 [35·0%] women and 450 [65·0%] men) were eligible for the discontinuation group and 935 individuals (339 [36·3%] women and 596 [63·7%] men) were eligible for the control group (median age in both groups: 39 years [IQR 30-47]). New somatic adverse events occurred in 295 (43%) individuals in the discontinuation group and 293 (31%) individuals in the control group (OR 1·74; 95% CI 1·27-2·39; τ2=0·15; moderate strength of evidence). New psychiatric adverse events were also more frequent in the discontinuation group than the control group (OR 2·01; 95% CI 1·38-2·94). Longer duration of treatment before discontinuation (OR for doubling the duration of treatment: 1·08; 95% CI 1·01-1·14) was associated with a higher probability of new somatic adverse events after antipsychotic discontinuation, and tapered discontinuation (compared with abrupt discontinuation: 0·54; 0·32-0·91) and no history of somatic illness (compared with history of somatic illness: 0·63; 0·43-0·91) were associated with lower probabilities of new somatic adverse events after antipsychotic discontinuation. The risk of bias was moderate in 13 (72·2%) studies and serious in five (27·8%) studies. INTERPRETATION: We detected moderate evidence of emerging somatic adverse events after discontinuation of first-generation and second-generation antipsychotics, particularly after discontinuation of longer durations of treatment. Tapered discontinuation can mitigate the risk of emerging somatic adverse events after antipsychotic discontinuation. These findings have implications for the safety of treatment discontinuation and could be used for tailored treatment planning. FUNDING: German Research Foundation.
引用
- Brandt L, Schneider-Thoma J, Siafis S, et al. Adverse events after antipsychotic discontinuation: an individual participant data meta-analysis. Lancet Psychiatry. 2022. PMID: 35183280. doi:10.1016/S2215-0366(22)00014-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。